These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
381 related articles for article (PubMed ID: 25435423)
1. ErbB2 signaling activates the Hedgehog pathway via PI3K-Akt in human esophageal adenocarcinoma: identification of novel targets for concerted therapy concepts. Kebenko M; Drenckhan A; Gros SJ; Jücker M; Grabinski N; Ewald F; Grottke A; Schultze A; Izbicki JR; Bokemeyer C; Wellbrock J; Fiedler W Cell Signal; 2015 Feb; 27(2):373-81. PubMed ID: 25435423 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of sonic hedgehog and PI3K/Akt/mTOR pathways cooperate in suppressing survival, self-renewal and tumorigenic potential of glioblastoma-initiating cells. Nanta R; Shrivastava A; Sharma J; Shankar S; Srivastava RK Mol Cell Biochem; 2019 Apr; 454(1-2):11-23. PubMed ID: 30251117 [TBL] [Abstract][Full Text] [Related]
3. Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma. Graab U; Hahn H; Fulda S Oncotarget; 2015 Apr; 6(11):8722-35. PubMed ID: 25749378 [TBL] [Abstract][Full Text] [Related]
10. PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth. Sharma N; Nanta R; Sharma J; Gunewardena S; Singh KP; Shankar S; Srivastava RK Oncotarget; 2015 Oct; 6(31):32039-60. PubMed ID: 26451606 [TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625 [TBL] [Abstract][Full Text] [Related]
12. Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors. Arnhold V; Boos J; Lanvers-Kaminsky C Cancer Chemother Pharmacol; 2016 Mar; 77(3):495-505. PubMed ID: 26781311 [TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors. Benvenuto M; Masuelli L; De Smaele E; Fantini M; Mattera R; Cucchi D; Bonanno E; Di Stefano E; Frajese GV; Orlandi A; Screpanti I; Gulino A; Modesti A; Bei R Oncotarget; 2016 Feb; 7(8):9250-70. PubMed ID: 26843616 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells. Li H; Jin X; Zhang Z; Xing Y; Kong X Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777 [TBL] [Abstract][Full Text] [Related]
15. DYRK1B blocks canonical and promotes non-canonical Hedgehog signaling through activation of the mTOR/AKT pathway. Singh R; Dhanyamraju PK; Lauth M Oncotarget; 2017 Jan; 8(1):833-845. PubMed ID: 27903983 [TBL] [Abstract][Full Text] [Related]
16. Gli-1 expression is associated with lymph node metastasis and tumor progression in esophageal squamous cell carcinoma. Mori Y; Okumura T; Tsunoda S; Sakai Y; Shimada Y Oncology; 2006; 70(5):378-89. PubMed ID: 17179732 [TBL] [Abstract][Full Text] [Related]
17. Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo. Wickström M; Dyberg C; Shimokawa T; Milosevic J; Baryawno N; Fuskevåg OM; Larsson R; Kogner P; Zaphiropoulos PG; Johnsen JI Int J Cancer; 2013 Apr; 132(7):1516-24. PubMed ID: 22949014 [TBL] [Abstract][Full Text] [Related]
18. Cross-signaling among phosphinositide-3 kinase, mitogen-activated protein kinase and sonic hedgehog pathways exists in esophageal cancer. Wei L; Xu Z Int J Cancer; 2011 Jul; 129(2):275-84. PubMed ID: 20839260 [TBL] [Abstract][Full Text] [Related]
19. Blockage of Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition. Jin HO; Lee YH; Park JA; Kim JH; Hong SE; Kim HA; Kim EK; Noh WC; Kim BH; Ye SK; Chang YH; Hong SI; Hong YJ; Park IC; Lee JK Biochem Biophys Res Commun; 2014 Feb; 444(4):502-8. PubMed ID: 24472538 [TBL] [Abstract][Full Text] [Related]
20. Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib. Amin DN; Ruiz-Saenz A; Gulizia N; Moasser MM Oncotarget; 2015 Dec; 6(38):41123-33. PubMed ID: 26516700 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]